Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.

摘要: Despite intense efforts to identify cancer-initiating cells in malignant brain tumours, markers linked the function of these have only very recently begun be uncovered. The notion cancer stem cell gained prominence, several molecules and signalling pathways becoming relevant for diagnosis treatment. Whether a substantial fraction or tiny minority tumor can initiate perpetuate cancer, is still debated. paradigm has initially been developed with respect blood cancers where chronic conditions such as myeloproliferative neoplasms are due mutations acquired haematopoietic (HSC), which maintains normal hierarchy neoplastic haematopoiesis. In contrast, acute leukaemia transformation appears derive not from HSCs but also committed progenitors that cannot differentiate. This review will focus on putative novel therapy targets represented by described define stem/initiating gliomas, called ‘leukaemia brain’, given their rapid migration evolution. Parallels drawn other cancers, especially haematopoietic, similar rampant proliferation treatment resistance glioblastoma multiforme secondary leukaemias. Genes associated expressed glioma intensively searched. Although many might coincidentally cells, some may oncogenic process, those would prime candidates diagnostic targeted therapy. For latter, combination therapies likely envisaged, robust plastic networks supporting proliferation.